Oral Drug Candidate Blocks Transmission of a Measles-Related Virus in Ferrets, but Human Efficacy Remains Unverified

Once measles enters a community with insufficient immunization coverage, its extreme transmissibility often leaves outbreak-control efforts struggling to catch up. Now, an oral antiviral drug candidate has demonstrated another possibility in ferret experiments: it may not only mitigate disease but also interrupt the virus’s spread to the next host before or after exposure.

The study, published in *Nature Microbiology*, tested GHP-88310. Because measles virus primarily infects humans, the team instead used canine distemper virus, which causes a measles-like disease in ferrets, as a surrogate model; both are closely related viruses in the genus *Morbillivirus*. Researchers either housed infected and uninfected ferrets together in direct contact or placed them in enclosures connected by directional airflow but without physical contact, separately modeling exposure through close contact and shared air.

In the prophylactic experiments, ferrets that began taking oral GHP-88310 twice daily shortly before exposure avoided disease following direct contact, and infection was prevented in the controlled-airflow setting. Twice-daily dosing that began three days after airborne exposure still completely suppressed detectable infection. With once-daily dosing, however, although the animals survived and had lower viral loads, some ferrets still developed antibodies, indicating that the virus had breached the drug’s defenses.

The drug also showed effects after infection had already become established. When exposed animals received treatment only after developing early symptoms, both illness and viral shedding were suppressed. When the originally infected ferrets responsible for spreading the virus were treated instead, their infectious period was shortened by five days, and sentinel animals exposed through contact or shared air showed no evidence of infection. This extends the drug’s potential role from protecting individuals to reducing the period during which a source of infection can transmit the virus to others.

GHP-88310 targets the virus’s RNA-dependent RNA polymerase, interfering with a core step required for viral genome replication and protein production. Georgia State University said this broad-spectrum orthomyxovirus polymerase inhibitor was developed by the university’s Center for Translational Antiviral Research. The research was funded by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, and preparations are currently underway for formal clinical testing.

These results provide proof of concept for whether drugs can be used to reduce transmission at the population level, not a clinical answer for treating measles. Canine distemper virus is not the same as human measles virus, and the doses, exposure conditions, and disease severity used in ferrets cannot be directly applied to humans. The study’s directional-airflow system was also designed to reproduce transmission consistently and remains different from the air environments in schools, homes, or healthcare settings.

Therefore, GHP-88310 cannot currently replace vaccination, and there are not yet any human data showing that it can prevent or treat measles. Subsequent clinical studies must clarify its safety, achievable drug concentrations, suitability for children, and how soon after exposure treatment would need to begin to potentially be effective. Only after these hurdles are cleared could the transmission chains shortened in the animal model have a chance of becoming an outbreak-control tool in real-world epidemics.